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Abstract
Background: Health and social conditions vary between West and East Germany.
Methods: We analyzed annual mortality data of all recorded deaths caused by lung, colorectal, breast and prostate
cancer in Germany as they are published by the Federal Bureau of Statistics (FBS) encompassing the period 1980–
2014 for former West Germany (WG) and 1990–2014 for former East Germany (EG). To compare East and West
Germany we computed the ratio of the mortality rates in both parts (mortality rate ratio, MRR, <1 indicates a lower
mortality in EG). Forecasting methods of time series analyses were applied (model selection based on the Box/
Jenkins approach) to predict 5-year trends until 2019.
Results: Lung cancer: In women mortality rose in both regions (WG: +2.8%, 1991–2014, EG: +2.2%, 1990–2014). In men
mortality in WG declined between −2.1% and −1.2%, and by −2.7% (1993–2009) in EG which was followed by a
plateau. Colorectal cancer: A decline was found in both WG (−3.1%, 1993–2014) and EG women (−3.8%, 1993–2008
and −2.0%, 2008–2014). A decline in EG men since 1992 (−0.9%, 1992–1997 and −2.3%, 1997–2014) mirrors the
development in WG (−2.6%, 1995–2014). Breast cancer: Constant mortality decline in WG after 1996. In EG a decline
(−2.4%, 1992–2007) was followed by a plateau with an MRR <1 (1990–2014). Prostate cancer: In WG a decline (−3.4%)
came to a hold after 2007, while there was a constant decline of 1.5% in EG. The forecast indicated that mortality of
colorectal/lung cancer in men and breast cancer reaches a plateau in future years.
Conclusion: Courses of mortality were similar between East and West, while existing differences are likely to remain in
the near future.
Background
It is a great achievement that cancer mortality has de-
creased in Europe since the early 1980s [1]. Unfortunately
cancer survival is not spread evenly over the continent.
While 5-year age and cancer site case-mix standardized
relative survival rate (ACRS) appears to be lowest in
Bulgaria for both men (32%) and women (47%), Austrian
men (53%) and Icelandic women (61%) currently have the
highest chances of survival [2]. Overall there is an ap-
proximately 9% lower probability of 5-year survival in
Eastern Europe compared to Central Europe.
One reason for this discrepancy might be found in dif-
fering socioeconomic welfare and health funding [3, 4].
The reunification of Germany in 1990 led to the estab-
lishment of a markedly different political and economic
system in the East, influencing a renewal in general
health care.
While cancer survival for a variety of sites was poorer
in the German Democratic Republic (GDR, East
Germany) compared to the Federal Republic of Germany
(FRG, West Germany) in the early 1980s, an ongoing
improvement in Eastern Germany has resulted in more
favourable treatment outcomes during the last years [5].
Jansen et al. estimated the 5-year age-standardized
relative survival rate for the 25 most common cancer lo-
calizations using data from 11 German cancer registries
for 2002–2006 [5]. Finding very similar survival rates for
20 of the analysed cancer sites (differences < 3%), the au-
thors concluded that there was a rapid closure of the
former survival gap between East and West Germany.
However, there were obvious advantages for patients suf-
fering from cancer of the gallbladder, oesophagus, oral
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cavity, or skin melanoma in the West and leukaemia in
the East.
An interesting question not answered by recent publica-
tions is whether Eastern Germany will eventually overtake
the rest of the country regarding cancer survival. The goal
of this study is to model future projections of mortality by
analysis and comparison of both West and East Germany




The annual mortality data of all recorded deaths in
Germany published by the Federal Bureau of Statistics
(FBS) was taken into account (Gesundheitsberichterstat-
tung des Bundes, www.gbe-bund.de). The available
period encompasses the time between 1980 and 2014 for
former West Germany and 1990 to 2014 for former East
Germany. We computed sex-specific mortality rates (per
100,000 inhabitants) after age standardization (world
standard population) separately for East and West
Germany. A direct age standardization approach with
five-year age intervals was used for each separate cancer.
In all analyses distinguishing between both areas of
Germany, the area of Berlin was excluded. This was due
to a divided Berlin; one part belonged to West Germany
and the other to the former East Germany. Mortality
data released by the FBS referred to the unified area of
Berlin without differentiating between its former parts.
Eventually, the area of Berlin was considered in an add-
itional analysis which is presented in the supplement.
We focused on the three most common types of
cancer-related deaths in Germany: lung cancer, colorec-
tal cancer, and prostate cancer in men and breast cancer
in women (Gesundheitsberichterstattung des Bundes,
www.gbe-bund.de).
Time series analysis and forecasting
Time series analysis and autoregressive integrated
moving average (ARIMA) were used for statistical
analyses. Model identification was based on the algo-
rithm introduced by Box and Jenkins [6, 7]. Details of
model identification and parameter estimation, includ-
ing the order of the selected ARIMA models, are pro-
vided in the Additional file 1. Based on the most
parsimonious ARIMA model (requiring the least mov-
ing average and autoregressive terms) that was in ac-
cordance with the Box/Jenkins approach, we applied
the “predict” function in R which uses an approach
based on the Kalman filter to forecast future mortal-
ity rates until the year 2019. This function also dis-
played their respective 95% confidence intervals.
To compare East and West Germany we computed
the ratio of the mortality rates in both areas (referred to
as mortality rate ratio, MRR). Both mortality rates and
MRRs underwent log transformation during statistical
analyses but were eventually re-transformed for illustra-
tive purposes. Similar to age-adjusted mortality, we per-
formed a time series analysis to forecast future MRR and
a joinpoint analysis considering the historical MRR data.
Joinpoint analysis
In addition to the time series analysis, we examined the
linear trends of the time series by means of a regression
based approach with time as the explanatory variable. A
joinpoint analysis was performed to identify time points
when alterations in the linear trend appear in the time
series [8]. We performed a permutation test with 2000
permutations allowing for a maximum of four join
points (trend alterations). Joinpoint analyses were per-
formed using the software package Joinpoint 4.2.0.2 de-
veloped by the Statistical Research and Applications
Branch, National Cancer Institute (NCI). The software
can be complimentarily downloaded from the NCI web-
page (http://surveillance.cancer.gov/joinpoint).
Internal validation
An internal validation was performed to assess the pos-
sible bias and the precision of the five year forecast
models by comparing the predicted with the observed
mortality from 2010–2014.
Sensitivity analysis
To estimate the impact of a possible disturbance in the
reported mortality by rearrangements in the coding sys-
tem during the transition period, we performed a sensi-
tivity analysis where the early years from 1990–1995
were excluded from the East German mortality data.
All further statistical analyses and data management




We estimated a constant growth of lung cancer mortal-
ity for German women overall. The site-specific rise was
higher for West German women (Table 2) with an an-
nual increase of 2.8% (95% CI: 2.7%, 2.9%, period 1991–
2014) than for East German women (Table 1) at 2.2%
(95% CI: 2.0%, 2.4%, period 1990–2014). Trend analyses
predicted a plateau in mortality for East German women
for the period after 2014, whereas mortality is predicted
to grow only minimally in West Germany (Fig. 1). Be-
tween 1990 and 2014 MRRs were below the equivalence
value of one, indicating that lung cancer specific death
was less common in East Germany as compared to West
Germany (Fig. 2). In women, it was estimated that the
MRR decreased (−0.6; 95% CI: −0.8, −0.4, Table 3)
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constantly during the observation period (increasingly
lower mortality in East Germany when compared to
West Germany). The difference in mortality is predicted
to stay constant for upcoming years as indicated by con-
fidence intervals considerably and constantly below the
equivalence value.
Lung cancer mortality in West German men declined
about 2.1% (95% CI: 2.1%, 2.2%) per year between 1991
and 2009, and 1.2% (95% CI: 0.6%, 1.7%) between 2009
and 2014 (Table 2). This process is expected to lose mo-
mentum through 2019 (Fig. 1). However, lung cancer
mortality in East German men increased about 4.4%
(95% CI: 0.7%, 8.2%) annually between 1990 and 1993,
followed by a decline of 2.7% (95% CI: 2.4%, 3.0%) for
the period 1993–2009 and a plateau phase with only a
minor, insignificant decline during 2009–2014 (Table 1).
The trend analysis revealed no further decrease in mor-
tality until 2019 (Fig. 1) for men in East Germany. The
MRR has remained above one since 1991, although the
lower 95% confidence limits are below one with a value
of 0.99 for future predictions. This describes a persist-
ently higher site-specific mortality in East Germany
(Fig. 2). The joinpoint analysis revealed a considerable
percentage increase in the MRR from 1990–1993 (5.6;
95% CI: 2.3, 9.0, Table 3), equivalent to an increasingly
disadvantageous situation in East Germany versus West
Germany. This development was reversed in subsequent
years by a slowly decreasing MRR, or an increasingly ad-
vantageous mortality in East Germany as compared to
West Germany.
Colorectal cancer
For East German women, an initial increase in mortality
(4.2%, 95% CI: −0.1%, 8.7%, 1990–1993) was followed by
an enduring decline of 3.8% (95% CI: 3.4%, 4.1%, 1993–
2008, Table 1) and 2.0% (95% CI: 0.6%, 3.3%, 2008–
2014). For West German women, we detected a constant
decrease of 3.1% (95% CI: 3.0%–3.2%, 1993–2014,
Table 2). The trend analysis predicted a similar annual
decline in West German females until 2019 (Fig. 3).
Between 1992 and 2014 MRR undulated consistently
around the equivalence value, illustrating a comparable
colorectal cancer mortality for East German and West
German women during this period which is expected to
stay constant until 2019 (Fig. 4). The MRR increased by
6.2% between 1990 and 1992, with almost no change in
the ratio of East German to West German cancer mor-
tality observed in later years (Table 3).
Table 1 Annual percentage mortality change in East Germany
with 95% confidence intervals
East
Men
Slope 1 Slope 2 Slope 3
Lung Year 1990–1993 1993–2009 2009–2014




































Estimates were computed using a Joinpoint analysis with 2000 permutations
Fig. 1 Time series of annual mortality rates for death from lung cancer in
Germany. Black: East Germany; Grey: West Germany. Solid lines represent the
estimates of the forecast with the respective 95% confidence intervals
(dashed lines)
Medenwald et al. BMC Cancer  (2017) 17:94 Page 3 of 10
The decrease in colorectal mortality in West Ger-
man males was unaltered between 1995 and 2014 at
2.6% (95% CI: 2.4%, 2.7%) annually (Table 2). In East
German men, a rise during the early years after re-
unification (10.9% 95% CI: 3.7%, 18.5%, 1990–1992)
was followed by a slower decrease of 0.9% (95% CI:
−1.3%, 2.9%, 1992–1997) and a stronger yearly decline
of 2.3% (1997–2014, Table 1). The MRR remained >1
between 2009 and 2014, indicating a survival benefit
in West German males (Fig. 4). For East German
men, the MRR increased by an estimated relative
change of 10.8% (1990–1992), yet decelerated from
1992 until 2014 (Table 3). It was predicted that this
trend would continue, and the mortality rate ratio
will undergo a slow decrease until 2019 (Fig. 3).
Breast cancer
The analysis of breast cancer mortality in East Germany
in the aftermath of reunification highlights a contrasting
picture (Table 1). After a noticeable annual decrease of
2.4% (95% CI: 2.0%, 2.7%) between 1992 and 2007, we
estimated a minor rise of 0.4% (95% CI: −0.6%, 1.5%)
Fig. 2 Ratio of annual mortality rates in East and West Germany for
death from lung cancer in Germany. The mortality rate ratio was
computed as the ratio of the annual age-standardized mortality in
East Germany to that in West Germany
Table 2 Annual percentage mortality change in West Germany
with 95% confidence intervals
West
Men
Slope 1 Slope 2 Slope 3 Slope 4
















































Estimates were computed using a Joinpoint analysis with 2000 permutations
Table 3 Annual percentage change in the ratio of East to West
German cancer mortality with 95% confidence intervals
between 1990 and 2014
Men
Slope 1 Slope 2
Lung Year 1990–1993 1993–2014
Estimate 5.6 [2.3, 9.0] −0.4 [−0.6, −0.3]
Prostate Year 1990–1992 1992–2014
Estimate 17.5 [3.0, 34.0] 1.0 [0.7, 1.3]
Colon/Rectum Year 1990–1992 1992–2014
Estimate 10.8 [4.3, 17.6] 0.3 [0.2, 0.5]
Women
Lung Year 1990–2014 -
Estimate −0.6 [−0.8, −0.4] -
Breast Year 1990–1996 1996–2014
Estimate −0.4 [−0.9, −0.0] 1.5 [0.2, 2.8]
Colon/Rectum Year 1990–1992 1992–2014
Estimate 6.2 [−4.3, 17.8] −0.3 [−0.5, −0.0]
Results refer to the relative change in the mortality rate ratio as computed by
means of a joinpoint procedure
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between 2007 and 2014. Breast cancer mortality was
lower in the former GDR for the entire time period
(MRR <1, 1990–2014; Figs. 5 and 6). Since 1996, in-
creasingly disadvantageous cancer mortality was ob-
served in East German women as compared to West
German women (Table 3). The trend analysis pre-
dicted a continuing survival benefit in East Germany
until 2019, though mortality in West Germany is ex-
pected to further decline (Fig. 6).
Prostate cancer
Mortality from prostate cancer was found to decline
slightly during the observational period of 1995–2006 by
3.4% per year (95% CI: 3.0%, 3.9%) in West Germany
(Table 2) but came to a halt afterwards. In East Germany
a weaker decline of 1.5% (95% CI: 1.2, 1.8%, 1993–2014)
per year endured until the end of the observational
period (Table 1). The forecast indicated virtually no
change in mortality in both parts of Germany, though
the wide confidence intervals need to be considered
(Fig. 5).
When comparing East and West Germany by means
of MMRs, it was found that mortality was slightly higher
in West Germany until the year 2000. As in the previous
analyses, the MRR rose considerably in the first years
after reunification (Table 3). The successive equivalence
of both parts in terms of mortality from prostate cancer
is expected to sustain in the upcoming years, although
confidence intervals are again wide (Fig. 6).
Internal validation
When we performed an internal validation (Additional
file 2: Figure S1 of the supplement), the bias estimated
as the mean of the difference between the predicted and
observed value (forecast error) was −2.1% (95% CI: −3.3,
−0.9). Thus, the presumed models tend to underestimate
the mortality by 2% on average. The precision of the
predicted mortality decreased in the 95% prediction in-
tervals, except for lung cancer in East German women.
In our example, the prediction intervals indicate a 95%
chance that the five-year forecast has an interval be-
tween 88.6% and 107.1% of the observed value. When
Fig. 3 Time series of annual mortality rates for death from colorectal
cancer in Germany. Black: East Germany; Grey: West Germany. Solid
lines represent the estimates of the forecast with the respective 95%
confidence intervals (dashed lines)
Fig. 4 Ratio of annual mortality rates in East and West Germany for
death from colorectal cancer in Germany. The mortality rate ratio
was computed as the ratio of the annual age-standardized mortality
in East Germany to that in West Germany
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female lung cancer mortality in East Germany is ex-
cluded, the interval narrows to 93.5% and 104.1%
respectively.
Sensitivity analysis (Additional file 3: Figure S2, Additional
file 4: Figure S3, Additional file 5: Figure S4, Additional
file 6: Figure S5, Additional file 7: Figure S6, Additional
file 8: Figure S7) and Berlin
In the sensitivity analysis, excluding the mortality re-
ported in early years, we found comparable point esti-
mates of the forecast but smaller confidence intervals
when death from colorectal cancer in men and the
MRR of prostate cancer was considered. The slope
changed towards a steeper decrease only in the case
of lung cancer mortality in men when compared with
the entire time series.
In regards to the results of Berlin, the mortality
from the remaining German population is mirrored
by this population, both in magnitude and trend
(Additional file 9: Figure S8, Additional file 10:
Figure S9, Additional file 11: Figure S10, Additional
file 12: Table S1).
Discussion
At first glance, the steep rise in cancer mortality after
the reunification of East Germany seems implausible.
General health care was expected to have improved dur-
ing this period of time in East Germany, and the physi-
ology of cancer renders fast changes in mortality
impossible. The actual cause for this might be based on
the different coding systems that the GDR and FRG used
in order to register causes of death [10, 11]. The struc-
ture of the GDR´s coding system is supposed to have led
to underreported cancer mortality before 1990 due to
subjective evaluation of the leading cause of death by the
certifying doctor. Thus, the adoption of West Germany’s
coding practice led to a more precise evaluation. The ef-
fect seems to be more pronounced in East German men,
which is likely affected by the overall higher cancer mor-
tality in this group.
Though there was a trend of young, healthy, and well-
educated East Germans migrating to West Germany es-
pecially in 1989/1990 (“selective migration”), the influ-
ence of this population shift on overall mortality
remains uncertain [11, 12]. For all cancer types,
Fig. 5 Time series of annual mortality rates for death from breast
and prostate cancer in Germany. Black: East Germany; Grey: West
Germany. Solid lines represent the estimates of the forecast with the
respective 95% confidence intervals (dashed lines)
Fig. 6 Ratio of annual mortality rates in East and West Germany for
death from breast and prostate cancer in Germany. The mortality
rate ratio was computed as the ratio of the annual age-standardized
mortality in East Germany to that in West Germany
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migration might be a factor that contributes to the ob-
served results. However, in this case migration should bias
towards cancer. That is, conditioning on age, people that
were less likely to get cancer should have been more likely
to migrate to West Germany. We expected a sharp de-
cline in cancer mortality after reunification, which is not
supported by the data. The typical late age at the time of
diagnosis made it unlikely that the vast majority of poten-
tial cases moved to either part of Germany. This line of
thought is more comprehensively followed in Luy et al.
Lung cancer
Smoking is undeniably the key contributor to lung can-
cer mortality worldwide [13].
An analysis of German microcensus data determined
the sex-specific proportion of current smokers from
1989 to 2009 [14]. While the rates for females remained
stable with 17.9% in 1989 and 18.9% in 2009, the num-
ber of male smokers dropped significantly from 36.7% to
27.5%. These findings of increasing mortality in women
and a decreasing trend in men might be closely linked to
the described differences in smoking behaviour.
Varying tobacco consumption is also a plausible ex-
planation for the reversing mortality difference among
East German and West German women as stressed in a
recent publication by Myrskylä et al. [15]. The authors
argued that smoking, which is more common among
West German women, led to a lower decline in
smoking-attributable mortality in this population as
compared to their East German counterparts. Lung can-
cer showed a more advantageous mortality in East
Germany, while mortality rates of other cancer types
were of comparable magnitude in both areas. Lower
mortality in East Germany was especially present in fe-
males between 50 and 64 years of age.
Our data matches with a prognosis by Malvezzi et al.
that calculated age-standardized mortality rates for the
European Union [16]. Between 2009 and 2015 they pre-
dicted a fall of 9.1% for males, but described a rise of
9.2% for females.
Colorectal cancer
A declining mortality from colorectal cancer was found
in our data. Using the WHO mortality database, Bosetti
et al. [17] determined an annual percent change in men
of −0.6% (1992–2003) and −2.0% (2003–2007), while a
continuous decline of 1.6% was detected in women.
Overall mortality in females was lower (10.51/100.000 in
2007) than in males (17.35/100.000).
A triad of improved early detection of disease, new
treatment options for more advanced stages, and a
healthier lifestyle in general may have driven the results.
The use of faecal occult blood testing and colonos-
copies as screening techniques allowed early detection of
adenomatous polyps as possible malignant precursors and
early stage tumours with a favourable prognosis [18, 19].
Tremendous therapeutic changes like new approaches in
surgery, the utilization of neoadjuvant chemoradiotherapy
for rectal carcinoma, and adjuvant chemotherapy proto-
cols contributed to higher cure rates [20–23].
A health conscious diet is an important aspect in the
prevention of colorectal cancer [24]. This might be a
feasible explanation for the geographical differences re-
garding mortality. Mensink et al. described a lower con-
sumption of cereals and leafy vegetables in East
Germans years after the reunification [25].
Though people should have been examined for colo-
rectal cancer starting at age 40 in the former GDR,
29.2% of cases with colon cancer and 24.7% of cases with
rectal cancer were diagnosed at stage IV in 1987. This is
a modest rise when compared to 1977 (24.3% and
19.7%) and could explain the increase that was observed
in 1990/1991 in East Germany [26].
Breast cancer
Numerous factors contributed to the general mortality
decrease during recent decades throughout Germany for
breast cancer patients.
First, there was tremendous improvement regarding
treatment strategies including the introduction of new
systemic therapy regimens (especially hormone therapy
and taxane-based chemotherapy), breast-conserving sur-
gery, and adjuvant radiotherapy [27–30].
The establishment of a nationwide screening program
in 2005 using x-ray mammography is expected to have led
to a significant rise in the detection of early stage disease,
although its effects are unlikely to have contributed con-
siderably to our findings. A synopsis of European
incidence-based mortality (IBM) studies investigating the
efficiency of breast cancer screening revealed a mortality
reduction of about 26% for a follow-up of 6–11 years [31].
Another explanation for declining mortality might be
found in a more restrictive prescription pattern of hor-
mone replacement therapy (HRT). Principal results from
the Women`s Health Initiative randomized controlled
trial revealed an increased breast cancer rate of about 26%
following HRT [32]. Katalinic et al. noticed a simultaneous
fall in HRT prescription and breast cancer incidence in
Germany, assuming a cause-effect relationship [33].
The overall lower breast cancer mortality in East
Germany is connected to the incidence, which is about
35% lower than in West Germany [34]. A reason for this
difference is based on differing reproductive histories of
East and West German women. It is known that preg-
nancy plays a protective role in breast cancer develop-
ment [35, 36]. An early first pregnancy and multiparity
are favourable contributors to a reduced breast cancer
lifetime risk [37]. A comparison of the fertility patterns
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for a cohort of 1961 showed that the median age at giv-
ing first birth was 27 years in West Germany and
22 years in East Germany [38]. The total number of
births in 40-year-old women was 1.62 in West Germany
and 1.84 in East Germany for the cohort of 1955.
In the former GDR, women above an age of 65 years
were less likely to receive additional treatment beyond
mastectomy or primary palliative care. This is indicated
by the number of inpatient treatments, which is close to
the number of incident cases in this age group. Further-
more, outpatient treatment of elderly patients was less
intense (lower cases when compared with the incidence)
and often confined to centres that were hard to reach
[26]. It can be argued that this disadvantageous situation
prevailed until 2007 when the decline in East Germany
reached a plateau.
Prostate cancer
Our findings illustrated a constant decline in prostate cancer
mortality. However, research revealed that the age-
standardized incidence of prostate cancer cumulated in the
year 2007 (Rate: 120.6 per 100,000 inhabitants) and declined
in later years (106.7/100,000 inhabitants in 2012), which thus
cannot serve as an explanation for our observations [39].
As prostate cancer is rarely affected by life style fac-
tors, an increasingly advantageous effect of secondary
prevention and/or therapy might account for the ob-
served mortality decline.
According to a German study that used register data
from the Munich area, both of these factors contributed
to the favourable mortality data. The authors stated that
a broader application of the PSA screening resulted in
the detection of small tumours and thus a higher pro-
portion of earlier T categories, from capsule-exceeding
to capsule-respecting (proportion of T1 increased from
14% to 32%). They also concluded that a change towards
more radical therapy regimens (from 20% to 50% from
1990 to 2010) led to improved survival [40].
Limitations
As a mere ecological study, this research cannot infer
any causal relations. The forecasts are based on previous
observations, thus future public health interventions or
treatment advances will have an additional effect that
cannot be modelled in the present study. However, past
trends were continuous for all considered cancer types
and no leaps were observed that could be attributed to
any particular intervention (public health or treatment).
Such a continuous time series can well be modelled by
means of time series analyses. In this context it must be
stated that statistical uncertainty for the majority of fore-
casts was considerable, as reflected by the wide confi-
dence intervals.
Conclusion
The overall trends and courses of cancer mortality were
similar between East and West Germany, though the exist-
ing differences are likely to continue in the near future.
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Additional file 1: Details of statistical analyses. (DOCX 27 kb)
Additional file 2: Figure S1. Internal validation. The forecast error was
computed as the percentage difference between the forecasted and
observed mortality. The bias was computed as the relative average
deviation of the forecasted from the observed values. Additionally,
prediction intervals of the forecast errors are displayed (confidence
intervals of each forecast, in contrast to the mean error which is
represented by the bias). (TIF 109 kb)
Additional file 3: Figure S2. Time series of annual mortality rates for
death from lung cancer in Germany excluding the early years (1990–
1995). Black: East Germany; Grey: West Germany. Solid lines represent the
estimates of the forecast with the respective 95% confidence intervals
(dashed lines). The time series covers the time between 1995 and 2014.
(TIF 109 kb)
Additional file 4: Figure S3. Ratio of annual mortality rates in East and
West Germany for death from lung cancer in Germany excluding the
early years (1990–1995). The mortality rate ratio was computed as the
ratio of the annual age-standardized mortality in East Germany to that in
West Germany. The time series covers the time between 1995 and 2014.
(TIF 80 kb)
Additional file 5: Figure S4. Time series of annual mortality rates for
death from colorectal cancer in Germany excluding the early years
(1990–1995). Black: East Germany; Grey: West Germany. Solid lines
represent the estimates of the forecast with the respective 95%
confidence intervals (dashed lines). The time series covers the time
between 1995 and 2014 (TIF 105 kb)
Additional file 6: Figure S5. Ratio of annual mortality rates in East and
West Germany for death from colorectal cancer in Germany excluding
the early years (1990–1995). The mortality rate ratio was computed as the
ratio of the annual age-standardized mortality in East Germany to that in
West Germany. The time series covers the time between 1995 and 2014.
(TIF 81 kb)
Additional file 7: Figure S6. Time series of annual mortality rates for
death from prostate and breast cancer in Germany excluding the early
years (1990–1995). Black: East Germany; Grey: West Germany. Solid lines
represent the estimates of the forecast with the respective 95%
confidence intervals (dashed lines). The time series covers the time
between 1995 and 2014 (TIF 106 kb)
Additional file 8: Figure S7. Ratio of annual mortality rates in East and
West Germany for death from prostate and breast cancer in Germany
excluding the early years (1990–1995). The mortality rate ratio was
computed as the ratio of the annual age-standardized mortality in East
Germany to that in West Germany. The time series covers the time be-
tween 1995 and 2014. (TIF 81 kb)
Additional file 9: Figure S8. Time series of annual mortality rates for
death from lung cancer in Berlin. Solid lines represent the estimates of
the forecast with the respective 95% confidence intervals (dashed lines).
(TIF 94 kb)
Additional file 10: Figure S9. Time series of annual mortality rates for
death from colorectal cancer in Berlin. Solid lines represent the estimates
of the forecast with the respective 95% confidence intervals (dashed
lines). (TIF 91 kb)
Additional file 11: Figure S10. Time series of annual mortality rates for
death from prostate and breast cancer in Berlin. Solid lines represent the
estimates of the forecast with the respective 95% confidence intervals
(dashed lines). (TIF 35 kb)
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Additional file 12: Table S1. Annual percentage cancer mortality
change in Berlin with 95% confidence intervals. Estimates were computed
using a joinpoint analysis with 2000 permutations. (DOCX 16 kb)
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